Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

globenewswire.com
GCTK The company reported reduced net loss, increased cash position, and progress in product development with patent approvals and anticipation of IDE submission and US clinical trials in 2026. This indicates positive momentum and future potential.

Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026

US Patent and Trademark Office (USPTO) issued patents for Glucotrack’s implantable

continuous blood glucose monitoring (CBGM) technology, strengthening the Company’s

intellectual property portfolio

Rutherford, NJ, March 30, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2025.

“In 2025 we made meaningful progress in advancing the development of our fully implantable continuous blood glucose monitoring technology and strengthening Glucotrack’s foundation. We strengthened our competitive position with three new patents issued by the USPTO and continued to work closely with the FDA on alignment as we progress toward securing IDE approval and initiating our U.S. clinical study program of our CBGM product,” said Paul V. Goode, PhD, President and Chief Executive Officer of Glucotrack. “We entered 2026 with strong momentum and a reinforced balance sheet, positioning the Company to execute on important development and regulatory milestones.”

Fourth Quarter 2025 & Recent Highlights

Corporate Highlights

Advanced Product and Clinical Development

Anticipated Milestones

Financial Results for the Year Ended December 31, 2025

Research and Development Expenses: Research and development expenses were $9.8 million for the full year 2025 compared to $9.5 million for the full year 2024. The increase of $0.3 million was primarily attributable to increased activities related to product design, development and manufacturing activities and pre-clinical animal studies.

General and Administrative Expenses: General and administrative expenses were $6.3 million for the full year 2025 compared to $5.1 million for the full year 2024. The increase of $1.2 million was primarily attributable to increased professional fees, personnel costs and placement agent fees.

Net Loss: Net loss for the full year 2025 was $19.4 million compared to a net loss of $22.6 million for the full year 2024. The decrease of $3.2 million was primarily attributable to non-cash losses of $7.5 million related to the settlement of debt and the issuance of warrants containing derivative features recognized in the prior year.

Cash Position: Cash and cash equivalents as of December 31, 2025, were $7.4 million, compared with $5.6 million in cash and cash equivalents as of December 31, 2024. The net increase of $1.8 million in cash and cash equivalents compared to December 31, 2024 was attributable to the $17.0 million from financing activities offset by cash used in operating and investing activities of $15.3 million.

Based on current plans and assumptions, the Company believes that its existing cash and cash equivalents will be sufficient to fund its 2026 operating plan by the end of Spring allowing for its IDE submission and initiate U.S. human clinical trials in 2026.

# # #

About Glucotrack, Inc.

Glucotrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.

Glucotrack’s Continuous Blood Glucose Monitor (CBGM) is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use.

For more information, please visit http://www.glucotrack.com. Information on the Company’s website does not constitute a part of and is not incorporated by reference into this press release.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “anticipate”, “believe”, “expect”, “plan” and “will” are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack’s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to the receipt (and timing) of regulatory approvals (including FDA approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack’s future distribution agreements; risks relating to its ability to hire and retain qualified personnel, including sales and distribution personnel; and the additional risk factors described in Glucotrack’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.

Contacts:

GLUCOTRACK INC.

CONSOLIDATED BALANCE SHEETS

GLUCOTRACK INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS